Breast Cancer Index®


Breast Cancer Index® test (BCI), performed by Biotheranostics, Inc., is the only test that is guideline-recognized to predict extended anti-estrogen therapy benefit.1-2

A New Standard for Extended Endocrine Therapy Decision-Making

Extending endocrine therapy beyond 5 years has been shown to reduce the risk of recurrence in some women with HR+, early-stage breast cancer. However, longer treatment is associated with significant potential side effects and adverse events, and many women do not benefit. 

Breast Cancer Index is a unique, proprietary genomic test that helps inform the appropriate duration of endocrine therapy by reporting two pieces of critical information:

  • Is she likely to benefit from extended endocrine therapy?
  • What is her individual risk of late distant recurrence (5-10 years post-diagnosis)?

SABCS 2023

Watch Drs. Rena Callahan*, UCLA Health, and VK Gadi*, University of Illinois Cancer Center, discuss evolving trends in HR+, early-stage breast cancer diagnostics.

JADPRO Live 2023

Watch a panel discussion on strategies to avoid over- and under-treatment in HR+, early-stage breast cancer with Linda Moors*, PA-C, Marla Sustin*, NP, and Mayra Lima*, APRN, MSN.

Hologic’s Breast Continuum of Care

From screening to survivorship, Hologic’s innovative and trusted breast health solutions help healthcare providers support women through their entire breast health journey. We apply cutting-edge science to accelerate discovery, improve efficiency and continually sharpen precision.

Breast health image

For Breast Cancer Index Intended Use and Limitations, visit the full site.

Biotheranostics, Inc., A Hologic Company
6333 Sequence Dr.,
San Diego, CA 92121
1 (877) 886-6739

Biotheranostics Licenses and Certifications

    *Speakers are paid consultants for Biotheranostics, Inc., a Hologic company. Statements reflect the speakers’ own personal views and interpretations.
    1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCNGuidelines®) for Breast Cancer V.1.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed January 25, 2024.To view the most recent and complete version of the guideline, go online to NCCN makes no warranties of anykindwhatsoeverregardingtheircontent,useorapplicationanddisclaimsanyresponsibilityfortheirapplicationoruseinany way. 2. AndreFet al. JClinOncol.Published online April19,2022.DOI:10.1200/JCO.22.00069 3. Davies C, et al. Lancet. 2013;381:805-816. 4. Gray R, et al. J Clin Oncol. 2013;31:(suppl; abstr 5). 5. Jakesz R, et al. J Natl Cancer Inst. 2007;99:1845-1853. 6. Goss PE, et al. J Natl Cancer Inst. 2005;97:1262-1271. 7. Mamounas EP, et al. NSABP B-42. GS4-01. SABCS 2019. 8. Goss PE, et al. N Engl J Med. 2016;375:209-219.